1 Department of Medicine, University of Massachusetts Medical School , Worcester, Massachusetts.
2 Department of Neurobiology, University of Massachusetts Medical School , Worcester, Massachusetts.
Hum Gene Ther. 2018 Jun;29(6):663-673. doi: 10.1089/hum.2017.199. Epub 2018 Feb 23.
Huntington's disease (HD) is a fatal neurodegenerative disease caused by a genetic expansion of the CAG repeat region in the huntingtin (HTT) gene. Studies in HD mouse models have shown that artificial miRNAs can reduce mutant HTT, but evidence for their effectiveness and safety in larger animals is lacking. HD transgenic sheep express the full-length human HTT with 73 CAG repeats. AAV9 was used to deliver unilaterally to HD sheep striatum an artificial miRNA targeting exon 48 of the human HTT mRNA under control of two alternative promoters: U6 or CβA. The treatment reduced human mutant (m) HTT mRNA and protein 50-80% in the striatum at 1 and 6 months post injection. Silencing was detectable in both the caudate and putamen. Levels of endogenous sheep HTT protein were not affected. There was no significant loss of neurons labeled by DARPP32 or NeuN at 6 months after treatment, and Iba1-positive microglia were detected at control levels. It is concluded that safe and effective silencing of human mHTT protein can be achieved and sustained in a large-animal brain by direct delivery of an AAV carrying an artificial miRNA.
亨廷顿病(HD)是一种致命的神经退行性疾病,由亨廷顿(HTT)基因中的 CAG 重复区域的遗传扩展引起。在 HD 小鼠模型中的研究表明,人工 miRNA 可以减少突变的 HTT,但在较大动物中缺乏其有效性和安全性的证据。HD 转基因绵羊表达全长人类 HTT,具有 73 个 CAG 重复。使用 AAV9 单侧递送至 HD 绵羊纹状体,在两个替代启动子(U6 或 CβA)的控制下靶向人类 HTT mRNA 的外显子 48 的人工 miRNA。该治疗在注射后 1 个月和 6 个月将纹状体中的人类突变型(m)HTT mRNA 和蛋白减少 50-80%。在尾状核和壳核中均可检测到沉默。治疗后 6 个月,用 DARPP32 或 NeuN 标记的神经元没有明显丢失,Iba1 阳性小胶质细胞的水平保持在对照水平。结论是,通过直接递送至携带人工 miRNA 的 AAV,可以在大型动物脑中实现并持续安全有效地沉默人类 mHTT 蛋白。